PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,095 | +41.1% | 3,095 | +94.9% | 0.00% | 0.0% |
| Q2 2023 | $22,740 | +100.6% | 1,588 | 0.0% | 0.00% | – |
| Q1 2023 | $11,338 | -18.3% | 1,588 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $13,879 | -18.4% | 1,588 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $17,000 | +30.8% | 1,588 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $13,000 | -40.9% | 1,588 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $22,000 | -29.0% | 1,588 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $31,000 | -39.2% | 1,588 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $51,000 | -5.6% | 1,588 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $54,000 | +54.3% | 1,588 | +71.7% | 0.00% | +100.0% |
| Q1 2021 | $35,000 | +12.9% | 925 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $31,000 | -8.8% | 925 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $34,000 | +13.3% | 925 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $30,000 | +25.0% | 925 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $24,000 | -17.2% | 925 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $29,000 | – | 925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |